Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Anti-myeloma activity and molecular logic operation by Natural Killer cells in microfluidic droplets.

Sarkar S, McKenney S, Sabhachandani P, Adler J, Hu X, Stroopinksy D, Rosenblatt J, Avigan D, Konry T.

Sens Actuators B Chem. 2019 Mar 1;282:580-589. doi: 10.1016/j.snb.2018.11.068. Epub 2018 Nov 17.

PMID:
31537955
2.

Endogenous thrombopoietin levels are elevated following double cord blood unit transplantation.

DeFilipp Z, Makar RS, Brown J, Avigan D, Chen YB, Cutler CS, Ballen KK, Kuter DJ.

Bone Marrow Transplant. 2019 Aug 28. doi: 10.1038/s41409-019-0652-8. [Epub ahead of print] No abstract available.

PMID:
31462685
3.

Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.

Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, Neuberg D, Takvorian RW, Hochberg EP, Bello CM.

Blood. 2019 Aug 15;134(7):606-613. doi: 10.1182/blood.2019001272. Epub 2019 Jun 11.

PMID:
31186274
4.

Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study.

Mateos MV, Orlowski RZ, Ocio EM, Rodríguez-Otero P, Reece D, Moreau P, Munshi N, Avigan DE, Siegel DS, Ghori R, Farooqui MZH, Marinello P, San-Miguel J.

Br J Haematol. 2019 Sep;186(5):e117-e121. doi: 10.1111/bjh.15946. Epub 2019 May 15. No abstract available.

PMID:
31090915
5.

Vulnerabilities in mIDH2 AML confer sensitivity to APL-like targeted combination therapy.

Mugoni V, Panella R, Cheloni G, Chen M, Pozdnyakova O, Stroopinsky D, Guarnerio J, Monteleone E, Lee JD, Mendez L, Menon AV, Aster JC, Lane AA, Stone RM, Galinsky I, Zamora JC, Lo-Coco F, Bhasin MK, Avigan D, Longo L, Clohessy JG, Pandolfi PP.

Cell Res. 2019 Jun;29(6):446-459. doi: 10.1038/s41422-019-0162-7. Epub 2019 Apr 25.

PMID:
31024166
6.

Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013.

Ribrag V, Avigan DE, Green DJ, Wise-Draper T, Posada JG, Vij R, Zhu Y, Farooqui MZH, Marinello P, Siegel DS.

Br J Haematol. 2019 Aug;186(3):e41-e44. doi: 10.1111/bjh.15888. Epub 2019 Apr 1. No abstract available.

PMID:
30937889
7.

Hypomethylating agent alters the immune microenvironment in acute myeloid leukaemia (AML) and enhances the immunogenicity of a dendritic cell/AML vaccine.

Nahas MR, Stroopinsky D, Rosenblatt J, Cole L, Pyzer AR, Anastasiadou E, Sergeeva A, Ephraim A, Washington A, Orr S, McMasters M, Weinstock M, Jain S, Leaf RK, Ghiasuddin H, Rahimian M, Liegel J, Molldrem JJ, Slack F, Kufe D, Avigan D.

Br J Haematol. 2019 May;185(4):679-690. doi: 10.1111/bjh.15818. Epub 2019 Mar 3.

8.

Cellular Immunotherapy for Multiple Myeloma.

Rosenblatt J, Avigan D.

Cancer J. 2019 Jan/Feb;25(1):38-44. doi: 10.1097/PPO.0000000000000356.

PMID:
30694858
9.

Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 Jun 29;16(1):179. doi: 10.1186/s12967-018-1552-1.

10.

Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.

Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J, Etna MP, Rieger S, Kempkes B, Coccia EM, Sui SJH, Chen CS, Uccini S, Avigan D, Faggioni A, Trivedi P, Slack FJ.

Leukemia. 2019 Jan;33(1):132-147. doi: 10.1038/s41375-018-0178-x. Epub 2018 Jun 26.

11.

Possible reactivation of chromosomally integrated human herpesvirus 6 after treatment with histone deacetylase inhibitor.

Politikos I, McMasters M, Bryke C, Avigan D, Boussiotis VA.

Blood Adv. 2018 Jun 26;2(12):1367-1370. doi: 10.1182/bloodadvances.2018015982. No abstract available.

12.

Cellular immunotherapy as a therapeutic approach in multiple myeloma.

Liegel J, Avigan D, Rosenblatt J.

Expert Rev Hematol. 2018 Jul;11(7):525-536. doi: 10.1080/17474086.2018.1483718. Review.

PMID:
29856648
13.

First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.

Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML.

J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6. Erratum in: J Transl Med. 2018 Jun 29;16(1):179.

14.

Prevention and treatment of relapse after stem cell transplantation with immunotherapy.

Gökbuget N, Canaani J, Nagler A, Bishop M, Kröger N, Avigan D.

Bone Marrow Transplant. 2018 Jun;53(6):664-672. doi: 10.1038/s41409-018-0232-3. Epub 2018 May 24. Review.

PMID:
29795427
15.

MUC1-C drives myeloid leukaemogenesis and resistance to treatment by a survivin-mediated mechanism.

Stroopinsky D, Rajabi H, Nahas M, Rosenblatt J, Rahimian M, Pyzer A, Tagde A, Kharbanda A, Jain S, Kufe T, Leaf RK, Anastasiadou E, Bar-Natan M, Orr S, Coll MD, Palmer K, Ephraim A, Cole L, Washington A, Kufe D, Avigan D.

J Cell Mol Med. 2018 May 15. doi: 10.1111/jcmm.13662. [Epub ahead of print]

16.

Vaccine therapy in hematologic malignancies.

Avigan D, Rosenblatt J.

Blood. 2018 Jun 14;131(24):2640-2650. doi: 10.1182/blood-2017-11-785873. Epub 2018 May 4. Review.

PMID:
29728403
17.

Phase 1 clinical trial evaluating abatacept in patients with steroid-refractory chronic graft-versus-host disease.

Nahas MR, Soiffer RJ, Kim HT, Alyea EP 3rd, Arnason J, Joyce R, Antin JH, Ho VT, Stroopinsky D, Li S, Levine JD, McMasters M, Jain S, Hamdan A, Tzachanis D, Bryant MP, Logan EK, Bazemore J, Stewart J, Joyce A, Stephenson S, Washington A, Cole L, Pyzer A, Leaf RK, Avigan DE, Rosenblatt J.

Blood. 2018 Jun 21;131(25):2836-2845. doi: 10.1182/blood-2017-05-780239. Epub 2018 Mar 16.

PMID:
29549175
18.

Anti-cancer vaccine therapy for hematologic malignancies: An evolving era.

Nahas MR, Rosenblatt J, Lazarus HM, Avigan D.

Blood Rev. 2018 Jul;32(4):312-325. doi: 10.1016/j.blre.2018.02.002. Epub 2018 Feb 15. Review.

PMID:
29475779
19.

A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia.

DeAngelo DJ, Brunner AM, Werner L, Avigan D, Fathi AT, Sperling AS, Washington A, Stroopinsky D, Rosenblatt J, McMasters M, Luptakova K, Wadleigh M, Steensma DP, Hobbs GS, Attar EC, Amrein PC, Ebert BL, Stone RM, Ballen KK.

Am J Hematol. 2018 Feb;93(2):254-261. doi: 10.1002/ajh.24968. Epub 2017 Nov 21.

20.

Targeting MUC1-C suppresses polycomb repressive complex 1 in multiple myeloma.

Tagde A, Markert T, Rajabi H, Hiraki M, Alam M, Bouillez A, Avigan D, Anderson K, Kufe D.

Oncotarget. 2017 Aug 10;8(41):69237-69249. doi: 10.18632/oncotarget.20144. eCollection 2017 Sep 19.

21.

DCOne as an Allogeneic Cell-based Vaccine for Multiple Myeloma.

Leaf RK, Stroopinsky D, Pyzer AR, Kruisbeek AM, van Wetering S, Washington A, Ephraim A, Cole L, Morin A, Jain S, Nahas MR, Apel A, Arnason J, Hamdan A, Rosenblatt J, Avigan D.

J Immunother. 2017 Nov/Dec;40(9):315-322. doi: 10.1097/CJI.0000000000000185.

PMID:
28961609
22.

Cabozantinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation.

Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ.

Cancer. 2018 Jan 15;124(2):306-314. doi: 10.1002/cncr.31038. Epub 2017 Sep 28. Erratum in: Cancer. 2018 May 15;124(10 ):2258.

23.

Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma.

Jain S, Washington A, Leaf RK, Bhargava P, Clark RA, Kupper TS, Stroopinsky D, Pyzer A, Cole L, Nahas M, Apel A, Rosenblatt J, Arnason J, Kufe D, Avigan D.

Mol Cancer Ther. 2017 Oct;16(10):2304-2314. doi: 10.1158/1535-7163.MCT-17-0060. Epub 2017 Jul 20.

24.

MUC1-C is a target in lenalidomide resistant multiple myeloma.

Yin L, Tagde A, Gali R, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D.

Br J Haematol. 2017 Sep;178(6):914-926. doi: 10.1111/bjh.14801. Epub 2017 Jun 23.

25.

MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs.

Pyzer AR, Stroopinsky D, Rosenblatt J, Anastasiadou E, Rajabi H, Washington A, Tagde A, Chu JH, Coll M, Jiao AL, Tsai LT, Tenen DE, Cole L, Palmer K, Ephraim A, Leaf RK, Nahas M, Apel A, Bar-Natan M, Jain S, McMasters M, Mendez L, Arnason J, Raby BA, Slack F, Kufe D, Avigan D.

Leukemia. 2017 Dec;31(12):2780-2790. doi: 10.1038/leu.2017.163. Epub 2017 May 30.

26.

Dendritic Cell Therapies for Hematologic Malignancies.

Weinstock M, Rosenblatt J, Avigan D.

Mol Ther Methods Clin Dev. 2017 Mar 18;5:66-75. doi: 10.1016/j.omtm.2017.03.004. eCollection 2017 Jun 16. Review.

27.

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity.

Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring MP, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP, Cantley LC.

Cancer Discov. 2017 Jul;7(7):750-765. doi: 10.1158/2159-8290.CD-16-0778. Epub 2017 Mar 8.

28.

MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia.

Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, Fung J, Bryant MP, Cole L, Palmer K, Somaiya P, Karp Leaf R, Nahas M, Apel A, Jain S, McMasters M, Mendez L, Levine J, Joyce R, Arnason J, Pandolfi PP, Kufe D, Rosenblatt J, Avigan D.

Blood. 2017 Mar 30;129(13):1791-1801. doi: 10.1182/blood-2016-07-730614. Epub 2017 Jan 26.

29.

Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1.

Bar-Natan M, Stroopinsky D, Luptakova K, Coll MD, Apel A, Rajabi H, Pyzer AR, Palmer K, Reagan MR, Nahas MR, Karp Leaf R, Jain S, Arnason J, Ghobrial IM, Anderson KC, Kufe D, Rosenblatt J, Avigan D.

Br J Haematol. 2017 Mar;176(6):929-938. doi: 10.1111/bjh.14493. Epub 2017 Jan 20.

30.

Increased Foxp3+Helios+ Regulatory T Cells and Decreased Acute Graft-versus-Host Disease after Allogeneic Bone Marrow Transplantation in Patients Receiving Sirolimus and RGI-2001, an Activator of Invariant Natural Killer T Cells.

Chen YB, Efebera YA, Johnston L, Ball ED, Avigan D, Lekakis LJ, Bachier CR, Martin P, Duramad O, Ishii Y, Han S, Jung YJ, Lee D, Kunkel L, Negrin RS, Bui JD.

Biol Blood Marrow Transplant. 2017 Apr;23(4):625-634. doi: 10.1016/j.bbmt.2017.01.069. Epub 2017 Jan 16.

31.

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.

Boyiadzis M, Bishop MR, Abonour R, Anderson KC, Ansell SM, Avigan D, Barbarotta L, Barrett AJ, Van Besien K, Bergsagel PL, Borrello I, Brody J, Brufsky J, Cairo M, Chari A, Cohen A, Cortes J, Forman SJ, Friedberg JW, Fuchs EJ, Gore SD, Jagannath S, Kahl BS, Kline J, Kochenderfer JN, Kwak LW, Levy R, de Lima M, Litzow MR, Mahindra A, Miller J, Munshi NC, Orlowski RZ, Pagel JM, Porter DL, Russell SJ, Schwartz K, Shipp MA, Siegel D, Stone RM, Tallman MS, Timmerman JM, Van Rhee F, Waller EK, Welsh A, Werner M, Wiernik PH, Dhodapkar MV.

J Immunother Cancer. 2016 Dec 20;4:90. doi: 10.1186/s40425-016-0188-z. eCollection 2016.

32.

Lack of impact of umbilical cord blood unit processing techniques on clinical outcomes in adult double cord blood transplant recipients.

Nikiforow S, Li S, Snow K, Liney D, Kao GS, Haspel R, Shpall EJ, Glotzbecker B, Sica RA, Armand P, Koreth J, Ho VT, Alyea EP 3rd, Ritz J, Soiffer RJ, Antin JH, Dey B, McAfee S, Chen YB, Spitzer T, Avigan D, Cutler CS, Ballen K.

Cytotherapy. 2017 Feb;19(2):272-284. doi: 10.1016/j.jcyt.2016.10.016. Epub 2016 Dec 9.

PMID:
27939176
33.

Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions.

Rosenblatt J, Stone RM, Uhl L, Neuberg D, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D.

Sci Transl Med. 2016 Dec 7;8(368):368ra171.

34.

Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?

Rosenblatt J, Avigan D.

Blood. 2017 Jan 19;129(3):275-279. doi: 10.1182/blood-2016-08-731885. Epub 2016 Dec 5. Review.

PMID:
27919908
35.

Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets.

Sarkar S, Sabhachandani P, Stroopinsky D, Palmer K, Cohen N, Rosenblatt J, Avigan D, Konry T.

Biomicrofluidics. 2016 Oct 12;10(5):054115. eCollection 2016 Sep.

36.

MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.

Tagde A, Rajabi H, Stroopinsky D, Gali R, Alam M, Bouillez A, Kharbanda S, Stone R, Avigan D, Kufe D.

Oncotarget. 2016 Jun 28;7(26):38974-38987. doi: 10.18632/oncotarget.9777.

37.

Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Davids MS, Kim HT, Bachireddy P, Costello C, Liguori R, Savell A, Lukez AP, Avigan D, Chen YB, McSweeney P, LeBoeuf NR, Rooney MS, Bowden M, Zhou CW, Granter SR, Hornick JL, Rodig SJ, Hirakawa M, Severgnini M, Hodi FS, Wu CJ, Ho VT, Cutler C, Koreth J, Alyea EP, Antin JH, Armand P, Streicher H, Ball ED, Ritz J, Bashey A, Soiffer RJ; Leukemia and Lymphoma Society Blood Cancer Research Partnership.

N Engl J Med. 2016 Jul 14;375(2):143-53. doi: 10.1056/NEJMoa1601202.

38.

MUC1 in hematological malignancies.

Stroopinsky D, Kufe D, Avigan D.

Leuk Lymphoma. 2016 Nov;57(11):2489-98. doi: 10.1080/10428194.2016.1195500. Epub 2016 Jun 27. Review.

39.

Myeloid-derived suppressor cells as effectors of immune suppression in cancer.

Pyzer AR, Cole L, Rosenblatt J, Avigan DE.

Int J Cancer. 2016 Nov 1;139(9):1915-26. doi: 10.1002/ijc.30232. Epub 2016 Jul 12. Review.

40.

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study.

Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, Millenson MM, Cohen AD, Schuster SJ, Lebovic D, Dhodapkar M, Avigan D, Chapuy B, Ligon AH, Freeman GJ, Rodig SJ, Cattry D, Zhu L, Grosso JF, Bradley Garelik MB, Shipp MA, Borrello I, Timmerman J.

J Clin Oncol. 2016 Aug 10;34(23):2698-704. doi: 10.1200/JCO.2015.65.9789. Epub 2016 Jun 6.

41.

Persistence of dysphagia and odynophagia after mediastinal radiation and chemotherapy in patients with lung cancer or lymphoma.

Shields H, Li J, Pelletier S, Wang H, Freedman R, Mamon H, Ng A, Freedman A, Come S, Avigan D, Huberman M, Recht A.

Dis Esophagus. 2017 Feb 1;30(2):1-8. doi: 10.1111/dote.12498.

PMID:
27247116
42.

Challenges in vaccine therapy in hematological malignancies and strategies to overcome them.

Nahas MR, Avigan D.

Expert Opin Biol Ther. 2016 Sep;16(9):1093-104. doi: 10.1080/14712598.2016.1190828. Epub 2016 Jun 13. Review.

PMID:
27220455
43.

Efficacy, durability, and response predictors of low-dose interleukin-2 therapy for chronic graft-versus-host disease.

Koreth J, Kim HT, Jones KT, Lange PB, Reynolds CG, Chammas MJ, Dusenbury K, Whangbo J, Nikiforow S, Alyea EP 3rd, Armand P, Cutler CS, Ho VT, Chen YB, Avigan D, Blazar BR, Antin JH, Ritz J, Soiffer RJ.

Blood. 2016 Jul 7;128(1):130-7. doi: 10.1182/blood-2016-02-702852. Epub 2016 Apr 12.

44.

Immune therapy in multiple myeloma.

Luptakova K, Avigan D.

Clin Adv Hematol Oncol. 2015 Nov;13(11):767-75. Review.

PMID:
27058703
45.

A combination of an anti-SLAMF6 antibody and ibrutinib efficiently abrogates expansion of chronic lymphocytic leukemia cells.

Yigit B, Halibozek PJ, Chen SS, O'Keeffe MS, Arnason J, Avigan D, Gattei V, Bhan A, Cen O, Longnecker R, Chiorazzi N, Wang N, Engel P, Terhorst C.

Oncotarget. 2016 May 3;7(18):26346-60. doi: 10.18632/oncotarget.8378.

46.

MUC1-C drives MYC in multiple myeloma.

Tagde A, Rajabi H, Bouillez A, Alam M, Gali R, Bailey S, Tai YT, Hideshima T, Anderson K, Avigan D, Kufe D.

Blood. 2016 May 26;127(21):2587-97. doi: 10.1182/blood-2015-07-659151. Epub 2016 Feb 23.

47.

Pilot experience with opebacan/rBPI 21 in myeloablative hematopoietic cell transplantation.

Guinan E, Avigan DE, Soiffer RJ, Bunin NJ, Brennan LL, Bergelson I, Brightman S, Ozonoff A, Scannon PJ, Levy O.

F1000Res. 2015 Dec 21;4:1480. doi: 10.12688/f1000research.7558.1. eCollection 2015.

48.

Role of Immune Therapies for Myeloma.

Rosenblatt J, Avigan D.

J Natl Compr Canc Netw. 2015 Nov;13(11):1440-7. Review.

PMID:
26553769
49.

Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies.

Karp Leaf R, Cho HJ, Avigan D.

Curr Hematol Malig Rep. 2015 Dec;10(4):395-404. doi: 10.1007/s11899-015-0283-0. Review.

PMID:
26338470
50.

Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma.

Jain S, Stroopinsky D, Yin L, Rosenblatt J, Alam M, Bhargava P, Clark RA, Kupper TS, Palmer K, Coll MD, Rajabi H, Pyzer A, Bar-Natan M, Luptakova K, Arnason J, Joyce R, Kufe D, Avigan D.

Blood. 2015 Jul 16;126(3):354-62. doi: 10.1182/blood-2015-02-628149. Epub 2015 Jun 5.

Supplemental Content

Loading ...
Support Center